Rathbun Communications, INC.

Athira Pharma announces publication in Frontiers in Neuroscience highlighting therapeutic potential of ATH-1105 in amyotrophic lateral sclerosis (ALS)

ATH-1105, a small molecule positive modulator of the neurotrophic HGF system, demonstrates significant neuroprotective effects and extends survival in preclinical models of ALS. The study highlights the therapeutic potential of ATH-1105 in slowing or stopping neurodegeneration.

SourceRathbun Communications, INC.·JournalFrontiers in Neuroscience·TypeExperimental study·DateFeb 8, 2024

De novo protein decoys block COVID-19 infection in vitro and protect animals in vivo

Neoleukin Therapeutics announces a novel protein decoy NL-CVX1 that blocks SARS-CoV-2 infection in vitro. The lead molecule is shown to protect hamsters from lethal doses of the virus through intranasal administration. This development demonstrates the potential of de novo protein design technology for addressing biological problems.

SourceRathbun Communications, INC.·JournalScience·DateNov 5, 2020

Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice

A new publication in Molecular Therapy outlines the dramatic effects of an exon skipping PPMO in preventing severe deterioration of dystrophin-deficient mice. The treatment restores dystrophin protein expression and maintains near-normal muscle function, suggesting great potential for treating Duchenne muscular dystrophy patients.

SourceRathbun Communications, INC.·JournalMolecular Therapy·DateOct 20, 2009